Following Sarepta’s Lead, Roche Suspends Elevidys Shipments to Some Ex-US Countries

Roche has voluntarily halted new deliveries of Sarepta's Duchenne muscular dystrophy gene therapy, Elevidys, to certain ex-U.S. markets that reference FDA approvals, mirroring Sarepta's U.S. shipment pause. This action follows two patient deaths associated with Elevidys in non-ambulatory patients, intensifying scrutiny on the drug's safety and its controversial full FDA approval in June 2024, which occurred despite a failed Phase III confirmatory study and internal agency dissent. Roche maintains a positive benefit-risk profile for ambulatory patients, continuing supply in other international markets.

Analysis

Roche's voluntary suspension of new Elevidys shipments in certain ex-U.S. markets, mirroring a similar U.S. pause by partner Sarepta Therapeutics, marks a significant escalation of risk for the Duchenne muscular dystrophy gene therapy. The halts are a direct response to two patient fatalities within the non-ambulatory cohort, attributed to acute liver failure, a known risk of the adeno-associated virus vector. This development severely compounds existing concerns surrounding Elevidys, which received full FDA approval in June 2024 despite failing its Phase III confirmatory study on functional mobility. The approval itself was controversial, reportedly pushed through by former FDA CBER director Peter Marks against the recommendation of agency reviewers, a move that has drawn public criticism and raises questions about regulatory governance. While Roche maintains that the benefit-risk profile remains positive for the ambulatory patient population, which has seen no fatalities across approximately 760 individuals, the dual headwinds of critical safety events and questionable efficacy data place the commercial viability of its $1.15 billion investment into serious doubt.

Key Decisions for Investors

• Investors in Sarepta (SRPT) face heightened risk as the safety and efficacy of its core commercial asset are now under intense regulatory and public scrutiny, making any further FDA or global regulatory action a critical catalyst for severe downside.
• For Roche (ROG) investors, while the direct financial impact is diluted by its scale, this event questions the due diligence behind its $1.15 billion ex-U.S. licensing deal and may signal broader challenges within its gene therapy pipeline.
• The key variable to monitor is the safety data within the ambulatory patient population; any new adverse events in this group would likely negate the companies' positive benefit-risk argument and could prove fatal to the therapy's market presence.
• The controversy surrounding the FDA's approval process could trigger a more stringent regulatory environment for all gene therapies, potentially increasing development risks and timelines for other companies in the biotech sector, especially those with marginal Phase III data.